This distinction underscores the importance of understanding the molecular characteristics of tumors and their response to statin therapy, suggesting the possibility of personalized treatment strategies based on the genetic profile of the tumor, such as targeting patients with p53 mutations for statin therapy. This evidence concerns the gene TP53 and neoplasm.